FIBROBIOLOGICS INC (FBLG)

Company Profile

Fibrobiologics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Houston, Texas. The company went IPO on 2024-01-31. FibroBiologics, Inc. is a cell therapy regenerative medicine company. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The firm is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat Multiple sclerosis (MS) and has completed the Phase I study. The firm is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing.

Company Info

FIBROBIOLOGICS INC

455 E. Medical Center Blvd, Suite 300

Houston TEXAS

P: 12816715152

Employees: 0

Website: https://fibrobiologics.com/